Tarsus Pharmaceuticals (TARS) Finished Goods (2023 - 2026)

Tarsus Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Finished Goods rose 51.47% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 51.47% YoY), while the FY2025 annual figure was $3.0 million, up 47.66% from the prior year.
• Finished Goods was $2.9 million for Q1 2026 at Tarsus Pharmaceuticals, down from $3.0 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $3.0 million in Q4 2025 to a low of $182000.0 in Q4 2023.
• Historically, Finished Goods has averaged $1.8 million across 4 years, with a median of $2.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Finished Goods soared 1002.2% in 2024, then surged 47.66% in 2025.
• A 4-year view of Finished Goods shows it stood at $182000.0 in 2023, then jumped by 1002.2% to $2.0 million in 2024, then jumped by 47.66% to $3.0 million in 2025, then slipped by 0.74% to $2.9 million in 2026.
• The last three Finished Goods figures came in at $2.9 million (Q1 2026), $3.0 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.